Maximilian Grant > Latham & Watkins LLP > Washington DC, United States > Lawyer Profile

Latham & Watkins LLP offers a team of experienced patent litigators with impressive ITC expertise, frequently representing major companies in high-profile litigation. Notable cases from the last year include achieving a favorable settlement for Jaguar Land Rover, successfully asserting five patents against The Chamberland Group on behalf of the Overhead Door Corporation, and representing Taiwan Semiconductor Manufacturing Company in an investigation linked to advanced semiconductor technology that is set to have industry-wide effects. Based in Washington DC, Bert Reiser and Jamie Underwood co-chair the ITC practice, both widely lauded for their expertise and litigious capabilities. Also based in Washington, Maximilian Grant, and Michael David are integral to the team, as is Douglas Lumish, who operates out of the firm’s Silicon Valley and San Francisco offices.

The patent litigation team at Latham & Watkins LLP  offers expertise across cross all aspects of intellectual property, evidenced by an impressive history of success for Fortune 100 and numerous blue-chip companies. The team is well-integrated and highly capable of handling complex disputes across jurisdictions, in district and federal court, the International Trade Commission, and the Patent Trial and Appeal Board. With experience across industries, the team regularly acts for major pharma companies, including Amgen, Biogen, Johnson & Johnson, Abbott Laboratories, Regeneron, and Eagle Pharmaceuticals. David Callahan from the firm’s Chicago office is the global chair of the practice, regularly acting as a first-chair trial lawyer. The global vice chairs include Tony Sammi in New York, Jeff Homrig in Austin, and Jennifer Barry in San Diego. In Silicon Valley, Douglas Lumish is a key lawyer in the team, frequently acting on high-profile and precedent-setting matters. Maximilian Grant and Matthew J. Moore in Washington DC are both integral figures, with extensive experience.